SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

Abstract

Significance This work shows that, under strong immune pressure, SARS-CoV-2 can use mutations in both the N-terminal domain and the receptor-binding domain to escape potent polyclonal neutralizing responses. Indeed, after a long period under immune selective pressure, SARS-CoV-2 evolved to evade the immunity of a potent polyclonal serum from a COVID-19 convalescent donor. Only three mutations were sufficient to generate this escape variant. The new virus was resistant to 70% of the neutralizing antibodies tested and had a decreased susceptibility to all convalescent sera. Our data predict that, as the immunity in the population increases, following infection and vaccination, new variants will emerge, and therefore vaccines and monoclonal antibodies need to be developed to address them.

Cited by papers we hold 22

• The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir · 2023
  No notice
• Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India · 2022
  Not checked
• The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges · 2022
  No notice
• Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera · 2021
  No notice
• Vaccines against Covid-19: Comparison, Limitations, the Decrease of Pandemic and the Perspective of Viral Respiratory · 2021
  Not checked
• Prolonged evolution of the human B cell response to SARS-CoV-2 infection · 2021
  No notice
• SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera · 2021
  Not checked
• A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants · 2021
  Not checked
• Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants · 2021
  No notice
• Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants · 2021
  No notice
• A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations · 2021
  Not checked
• Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 · 2021
  No notice
• SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern · 2021
  No notice
• Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies · 2021
  Corrected
• Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies · 2021
  No notice
• Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2 · 2021
  No notice
• Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? · 2021
  No notice
• SARS-CoV-2 one year on: evidence for ongoing viral adaptation · 2021
  No notice
• Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice · 2021
  No notice
• Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 · 2021
  No notice

and 2 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.